Levopod-OD Tablet contains Levosulpiride 75 mg, a selective dopamine D2 receptor antagonist with prokinetic and antipsychotic properties. It is primarily indicated for the treatment of gastrointestinal motility disorders such as functional dyspepsia, gastroesophageal reflux disease (GERD), and diabetic gastroparesis. Levosulpiride enhances gastrointestinal motility by blocking inhibitory dopamine receptors in the gut, thereby promoting gastric emptying and improving symptoms like nausea, vomiting, bloating, and abdominal discomfort. Additionally, it exhibits central nervous system effects useful in managing psychiatric conditions including depression and schizophrenia, particularly for alleviating negative symptoms and cognitive dysfunction. Levopod-OD Tablet is formulated for oral disintegration, facilitating ease of administration without the need for water, which improves patient compliance. The recommended dosage varies based on the clinical indication and patient response, typically ranging from 25 to 75 mg daily, administered before meals. Caution is advised in patients with prolactin-dependent tumors, epilepsy, or severe renal impairment. Common adverse effects include drowsiness, dizziness, and extrapyramidal symptoms, which are generally dose-dependent and reversible upon discontinuation. Levopod-OD should be used under medical supervision, considering potential drug interactions and contraindications.